Quality and safety requirements for sustainable phage therapy products. - Wikidata - wikimedia - TriplyDB

Quality and safety requirements for sustainable phage therapy products.

Quality and safety requirements for sustainable phage therapy products.

http://www.wikidata.org/entity/Q35674419

about

Bacteriophage Procurement for Therapeutic Purposes Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases Strain Specific Phage Treatment for Staphylococcus aureus Infection Is Influenced by Host Immunity and Site of Infection φBO1E, a newly discovered lytic bacteriophage targeting carbapenemase-producing Klebsiella pneumoniae of the pandemic Clonal Group 258 clade II lineage The Janus-Face of Bacteriophages across Human Body Habitats.Bacteriophages as Potential Treatment for Urinary Tract Infections Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus.Silk route to the acceptance and re-implementation of bacteriophage therapy.A bacteriophage journey at the European Medicines Agency.Bacteriophage therapy: a regulatory perspective.Genetically modified bacteriophages in applied microbiology.Paenibacillus larvae-Directed Bacteriophage HB10c2 and Its Application in American Foulbrood-Affected Honey Bee Larvae.Pseudomonas predators: understanding and exploiting phage-host interactions.Characterization of vB_SauM-fRuSau02, a Twort-Like Bacteriophage Isolated from a Therapeutic Phage Cocktail.Alternatives to antibiotics.Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework.Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release.Bacteriophage Production in Compliance with Regulatory Requirements.Guidelines to Compose an Ideal Bacteriophage Cocktail.Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains.In Vitro Characteristics of Phages to Guide 'Real Life' Phage Therapy Suitability.Optimizing Propagation of Staphylococcus aureus Infecting Bacteriophage vB_SauM-phiIPLA-RODI on Staphylococcus xylosus Using Response Surface Methodology.The disparate effects of bacteriophages on antibiotic-resistant bacteria Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles Characterization of vB_Kpn_F48, a Newly Discovered Lytic Bacteriophage for Klebsiella pneumoniae of Sequence Type 101

P2860

Q26738479-ADC35D2B-5609-4218-AB2F-6779C33C12F7 Q28069939-4C028A29-D9BE-4F86-9924-C6807D71E5EA Q28546694-EACCAFCA-FD50-40B4-B8EB-C352DFC1AC04 Q30402653-4593DDDA-A0EE-4A1D-8456-B17BEBF0EFBD Q36060279-511D3830-4B28-4EAB-ABFD-C7EE47D08056 Q36784640-CC5EF6B0-7CB8-408F-8E04-9F684C4BB07B Q37712935-A3D75EF0-36E1-4C3D-8C49-A99D7D339D38 Q38381910-0380D976-CF7F-4F1B-A6FA-A05F67ED8574 Q38560900-BF197A78-7F56-46B8-9F40-44D66FD2D536 Q38805538-0A1FA38B-6E41-4B0D-A4FF-51A317EE3036 Q38870317-5ADF470A-6BA0-4CB0-928E-07013FA0EFAB Q38998688-CBD27917-7C5D-4F45-B904-894A479E05D3 Q39397651-48A981CA-B98F-4BB2-8FFF-0A22B730B3F0 Q40041460-85AEC947-674E-4744-A744-B2939372B8D7 Q40733237-AE31FBD2-05DB-4C90-89A9-6378DEE6028D Q40867366-260BDACE-3AD5-4AC6-A1B4-81025D17B555 Q41918244-FF8566EA-F5A4-456D-866C-F0A4C2F658DD Q50100571-14EBCFE4-5429-4D9E-B7CA-8DCF5072FBDE Q50100609-5E76864C-06F5-4327-97F6-86CF23B69C8A Q52604672-663C1A24-4FD8-4A29-86D2-9D6F80FF3C7D Q53699945-F2EC6690-E570-4FF9-812A-9A875329863A Q54247479-8C94A1DB-503E-4DB3-8E7B-5D57EE909295 Q57283588-0D4EAE54-E296-4973-971D-DB3B4DEEFFE4 Q58571995-7C533113-0321-41A2-896E-C84F140D7E47 Q58757038-8F2B49D9-AD82-4D86-A951-6D24B94F14A5

P2860

Quality and safety requirements for sustainable phage therapy products.

http://www.wikidata.org/entity/Q35674419

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Quality and safety requirements for sustainable phage therapy products.

@ast

Quality and safety requirements for sustainable phage therapy products.

@en

type

label

Quality and safety requirements for sustainable phage therapy products.

@ast

Quality and safety requirements for sustainable phage therapy products.

@en

prefLabel

Quality and safety requirements for sustainable phage therapy products.

@ast

Quality and safety requirements for sustainable phage therapy products.

@en

P1433

Q35674419-70248317-CAD4-4EE5-A2D4-4F67887A318C

P1476

Q35674419-954A88F4-5912-4A1C-8452-7FDDFE922420

P2093

Q35674419-18E5605C-7615-45A0-B1AA-5137F646CFF4

Q35674419-23DB35B5-9090-4FD4-9BDE-7BF1721BEB4F

Q35674419-4F1FB01D-D6F1-4F00-A690-C5C903DE21AC

Q35674419-54E7C818-AF0B-45AD-AA4B-E6FBE67EFC88

Q35674419-589D9804-2AE8-4433-B903-50BC3DEF9390

Q35674419-73BEF945-4AA2-4F7F-8C1B-B3FD27829B73

Q35674419-832DF15E-B159-42C3-A23F-095F1D560E23

Q35674419-9120CF89-1048-456B-B200-5EF640F12F79

Q35674419-94ACD227-56E7-47A9-8272-9F7EC10863F2

Q35674419-9549D9A9-07E2-4BA6-B607-FCFE0F8258AD

P2860

Q35674419-230CB3F2-CD51-4524-BFCD-B184E2DD47A8

Q35674419-2CAD2D14-489A-4329-853A-7F4E65191A97

Q35674419-34D8942D-F260-4E15-B231-FEF4A6A94EA1

Q35674419-3B0B7D9A-E9B2-4D7E-B909-6C9373890987

Q35674419-4AAEFBFE-B236-4782-8BE1-B26F2CEFE29C

Q35674419-4B668A10-5466-4678-9F7F-CC67C8778CA9

Q35674419-53AB15DA-D852-4B34-BFE5-9E024D6F43F6

Q35674419-57E707AB-4D58-4ACD-801E-9BBF1ADFC01D

Q35674419-766ECBE3-5553-4FE6-A105-023C4D1C78F0

Q35674419-76D00F3F-FAA8-4B44-9623-6FF2E0B7CF2D

P304

Q35674419-589F6A2E-8CA2-4970-8EEE-1DFB77151A4E

P31

Q35674419-1A5E7E00-1281-4958-B46F-9DC3EC8323D2

P356

Q35674419-29B28B1C-CE65-408F-8F84-C4C5E67BF41D

P433

Q35674419-69D32E41-FCB9-4518-9D04-012BB170873D

P478

Q35674419-5782C1F7-F9ED-41F7-92E4-BDD8B7B24DA1

P50

Q35674419-1C3DF3DE-3D14-4E51-A06F-F7BAB3822073

Q35674419-2A04A836-E971-430C-8EB5-D3A1588ABCDF

Q35674419-5DAEFC41-85A9-415E-B921-33F5A43AB771

Q35674419-6B305D11-F179-4A82-9694-DD08D35792E4

Q35674419-7053DB4D-3874-4F0A-8727-F321D062DF1F

Q35674419-8409F1E5-CB9B-4AE9-99AA-0B690C0DCFB8

Q35674419-D2ADE804-DA7C-4AFA-9DB5-B6703524D0B2

P577

Q35674419-5D86FA16-9998-45C9-A963-4DABFC676936

P5875

Q35674419-E6C8BBFF-8C30-48AE-B1DD-8B80F9733186

P698

Q35674419-0AC76495-D7EE-47A2-A354-8CC7DFAADD0B

P932

Q35674419-C4CBA385-8C29-48C0-AC38-DB67D630278D

P356

S11095-014-1617-7

P1433

Pharmaceutical Research

P1476

Quality and safety requirements for sustainable phage therapy products.

@en

P2093

Alain Dublanchet

http://www.w3.org/2001/XMLSchema#string

Andrzej Górski

http://www.w3.org/2001/XMLSchema#string

Bob G Blasdel

http://www.w3.org/2001/XMLSchema#string

Christine Rohde

http://www.w3.org/2001/XMLSchema#string

Daniel De Vos

http://www.w3.org/2001/XMLSchema#string

Elizabeth Kutter

http://www.w3.org/2001/XMLSchema#string

Ewa Olchawa

http://www.w3.org/2001/XMLSchema#string

Flavie Pouilot

http://www.w3.org/2001/XMLSchema#string

Gilbert Verbeken

http://www.w3.org/2001/XMLSchema#string

Gregory Resch

http://www.w3.org/2001/XMLSchema#string

P2860

Pirates of the Caudovirales

Viunalikeviruses are environmentally common agents of horizontal gene transfer in pathogens and biocontrol bacteria.

Digitized fluorescent RFLP analysis (fRFLP) as a universal method for comparing genomes of culturable dsDNA viruses: application to bacteriophages.

Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany

Evolutionary consequences of intra-patient phage predation on microbial populations.

Gene transfer agents: phage-like elements of genetic exchange

Tackling antibiotic resistance.

The role of regulated clinical trials in the development of bacteriophage therapeutics.

Antibacterial efficacy of temperate phage-mediated inhibition of bacterial group motilities.

A genetic approach to the development of new therapeutic phages to fight pseudomonas aeruginosa in wound infections.

P304

2173-2179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-014-1617-7

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Mario Vaneechoutte

Laurent Debarbieux

Jean-Paul Pirnay

Nina Chanishvili

P577

2015-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270965599

http://www.w3.org/2001/XMLSchema#string

P698

25585954

http://www.w3.org/2001/XMLSchema#string

P932

4452253

http://www.w3.org/2001/XMLSchema#string